# Anetumab Ravtansine and Atezolizumab in Treating Participants With Advanced Non-small Cell Lung Cancer

> **NCT03455556** · PHASE1 · TERMINATED · sponsor: **Mayo Clinic** · enrollment: 1 (actual)

## Conditions studied

- Mesothelin Positive
- Stage III Non-Small Cell Lung Cancer AJCC v7
- Stage IIIA Non-Small Cell Lung Cancer AJCC v7
- Stage IIIB Non-Small Cell Lung Cancer AJCC v7
- Stage IV Non-Small Cell Lung Cancer AJCC v7

## Interventions

- **BIOLOGICAL:** Anetumab Ravtansine
- **BIOLOGICAL:** Atezolizumab
- **OTHER:** Laboratory Biomarker Analysis

## Key facts

- **NCT ID:** NCT03455556
- **Lead sponsor:** Mayo Clinic
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2018-08-10
- **Primary completion:** 2019-09-11
- **Final completion:** 2020-01-07
- **Target enrollment:** 1 (ACTUAL)
- **Why stopped:** slow accrual
- **Last updated:** 2023-01-06

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03455556

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03455556, "Anetumab Ravtansine and Atezolizumab in Treating Participants With Advanced Non-small Cell Lung Cancer". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT03455556. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*